Stock Ratings / Industrials / DBD / financials

PBI (66) NATL (56) VYX (31) PAR (31) ⌘ Pro Terminal →

Diebold Nixdorf Incorporated (DBD) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: Is DBD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Diebold Nixdorf Incorporated (NYSE: DBD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $59.14 (+1.84% 1D, market cap $1.99B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 485 tracked Industrials issuers, DBD ranks #153 in composite RQD confidence.

Q: How does DBD compare to PBI and NATL in the Industrials sector?

Within the Industrials sector (Office Equipment/Supplies/Services), DBD carries a Roarable C- (61/100 RQD), trailing P/E of 21.0x, gross margin of 25.3%, and ROIC of 11.5%. By comparison, PBI (Pitney Bowes Inc.) holds a C+ grade (66/100 RQD, P/E 15.6x, ROIC —, cap $2.26B) and NATL (NCR Atleos Corporation) posts a D+ grade (56/100 RQD, P/E 20.9x, ROIC 14.4%, cap $3.38B). Among the 5-stock peer group, PBI leads on earnings multiple (15.6x) while NATL leads on capital efficiency (14.4% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for DBD?

Per DBD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000028823), Diebold Nixdorf Incorporated generated $3.81B in revenue (+1.5% YoY), $94.6M in net income, and $300.7M in free cash flow against $3.85B in total assets and $938.5M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is DBD trading relative to its 50-day, 200-day, and 52-week technical levels?

DBD last traded at $59.14 (+1.84% on volume of 685,821 shares), positioning the stock -9.22% below its 50-day simple moving average ($65.15) and -21.10% below its 200-day simple moving average ($74.96). Across its 52-week range of $52.87 to $92.09, DBD sits at the 16.0% percentile with a 14-day RSI of 27.7 (OVERSOLD (<32)) and an implied next-earnings move of ±8.5% ($54.11 to $64.17).

Q: How profitable is Diebold Nixdorf Incorporated (DBD)?

In FY 2025 (10-K), DBD converted $3.8B of revenue into a 25.3% gross margin, 6.4% operating margin, and $300.7M in free cash flow (7.9% FCF margin).

$59.14 +1.84% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $59.22

Diebold Nixdorf Incorporated (DBD) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $1.99B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $59.22 (+0.14%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 7.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DBD)Realized 20D OHLCV Swing Band: ±8.5%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY DBD SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+16/20 pts (26% of score)

SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (21% of score)

FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 27.7 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$63.67+5% Next Q

Q2 (-2Q)

Grade B-$66.83+3.5% Next Q

Q3 (-1Q)

Grade C+$69.18-14.5% Next Q

Current

Grade C-$59.14+0.5% Hist 90D α

Trajectory: B- (69) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the DBD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, DBD faces multiple-compression risk if 21.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 22.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($65.15) or 200D SMA ($74.96) invalidates the momentum regime and cuts Target Base ($59.94) toward Bear Floor ($46.75).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DBD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DBD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How DBD Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$300.7M (7.9% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY24

Rev $3.75B

FY25

Rev $3.81B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$3.81B	25.3%	6.4%	$94.6M	$300.7M	11.5%
FY 2024	$3.75B	24.5%	4.9%	-$16.5M	$149.2M	9.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DBD)

✓Walkthrough of DBD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DBD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.00%📐 HORIZONTAL RANGE

2026-10-30O $58.39H $59.14L $52.87C $59.14VOL 739.9K

RES: $105.4SUP: $53.42SMA50: $65.15SMA200: $74.96

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DBD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DBD Butterfly Map → + Track DBD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

14.6%/yr Implied 5Y Growth

vs. +1.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DBD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DBD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DBD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DBD)

Industrials Rank #153 of 485 ⚔️ PBI vs DBD Full Matrix →

1. Head-to-Head Industrials Peer Comparison (DBD vs. PBI, NATL, VYX, PAR)

Industry: Office Equipment/Supplies/Services (13 Tracked Issuers)

Across 485 tracked Industrials securities in the Roarable RQD universe, Diebold Nixdorf Incorporated (DBD) ranks #153 by composite RQD confidence (61/100, grade C-) and #211 by equity capitalization ($1.99B). Within this direct 5-issuer industry benchmark cohort, PBI leads on earnings valuation at 15.6x trailing P/E, while NATL leads on capital efficiency and profitability with 14.4% ROIC and — gross margin. PBI currently holds the highest overall quantitative score in the immediate peer group at 66/100 (C+) compared with DBD at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DBD ACTIVE Diebold Nixdorf Incorporated	C-	61/100	21.0x	25.3%	11.5%	+1.84%	$1.99B	Benchmark Subject
PBI Pitney Bowes Inc.	C+	66/100	15.6x	—	—	-5.62%	$2.26B	/pbi-vs-dbd →
NATL NCR Atleos Corporation	D+	56/100	20.9x	—	14.4%	+0.93%	$3.38B	/natl-vs-dbd →
VYX NCR Voyix Corporation	E	31/100	18.3x	—	1.1%	+3.27%	$1.13B	/vyx-vs-dbd →
PAR PAR Technology Corporation	E	31/100	—	43.5%	-4.9%	+3.55%	$736.3M	/par-vs-dbd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000028823

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Diebold Nixdorf Incorporated (DBD) reported GAAP revenue of $3.81B (+1.5% vs. FY2024 revenue of $3.75B ) , GAAP net income of $94.6M, operating cash flow of $300.7M, and free cash flow of $300.7M (+101.5% YoY). On the balance sheet, DBD closed FY2025 with $3.85B in total assets against $938.5M in total debt (Altman Z-Score: 1.79, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.81B	$94.6M	$300.7M	$300.7M	$3.85B	$938.5M
FY2024 (FY)	2024-12-31	$3.75B	-$16.5M	$149.2M	$149.2M	$3.54B	$927.3M

3. DBD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DBD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Diebold Nixdorf Incorporated (NYSE: DBD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $59.14 (+1.84% 1D, market cap $1.99B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 485 tracked Industrials issuers, DBD ranks #153 in composite RQD confidence.

How does DBD compare to PBI and NATL in the Industrials sector?

Within the Industrials sector (Office Equipment/Supplies/Services), DBD carries a Roarable C- (61/100 RQD), trailing P/E of 21.0x, gross margin of 25.3%, and ROIC of 11.5%. By comparison, PBI (Pitney Bowes Inc.) holds a C+ grade (66/100 RQD, P/E 15.6x, ROIC —, cap $2.26B) and NATL (NCR Atleos Corporation) posts a D+ grade (56/100 RQD, P/E 20.9x, ROIC 14.4%, cap $3.38B). Among the 5-stock peer group, PBI leads on earnings multiple (15.6x) while NATL leads on capital efficiency (14.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DBD?

Per DBD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000028823), Diebold Nixdorf Incorporated generated $3.81B in revenue (+1.5% YoY), $94.6M in net income, and $300.7M in free cash flow against $3.85B in total assets and $938.5M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DBD trading relative to its 50-day, 200-day, and 52-week technical levels?

DBD last traded at $59.14 (+1.84% on volume of 685,821 shares), positioning the stock -9.22% below its 50-day simple moving average ($65.15) and -21.10% below its 200-day simple moving average ($74.96). Across its 52-week range of $52.87 to $92.09, DBD sits at the 16.0% percentile with a 14-day RSI of 27.7 (OVERSOLD (<32)) and an implied next-earnings move of ±8.5% ($54.11 to $64.17).

DBD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Diebold Nixdorf Incorporated (DBD)?

In FY 2025 (10-K), DBD converted $3.8B of revenue into a 25.3% gross margin, 6.4% operating margin, and $300.7M in free cash flow (7.9% FCF margin).

Direct Sub-Reports: DBD RQD Cockpit DBD 12M Forecast DBD Earnings & Move DBD Dividends & DRIP DBD Insiders & 13F DBD Whale Options DBD Profit Sankey DBD News & Why